Here are five observations:
1. For the second quarter, the company’s sales topped $111.5 million, a 2.4 percent increase year-over-year.
2. Orthofix’s spine fixation business segment generated $23.9 million in sales, an 11.8 percent increase year-over-year.
3. Within its biologics segment, Orthofix reported $17.7 million in sales, a 6.3 percent decrease year-over-year.
4. Orthofix reported $24.8 million in sales for its extremity fixation segment, a 0.2 percent increase year-over-year.
5. The company predicts its full-year sales to range between $450 million to $456 million.
To view the full financial report, click here.
More articles on devices and implants:
Fuse Medical completes Maxim Surgical acquisition
Alphatec sets sights on 12 new product launches: 3 things to know about the rest of the year
Zimmer Biomet names 2 industry veterans to board of directors — 4 things to know
